NYSE:DHRLife Sciences
Assessing Danaher’s Prospects After a 22% Drop and Outlook for 2025
If you have Danaher on your watchlist, you are not alone in wondering whether now is the right moment to act. The past year has been a wild ride for the stock, dragging it down by 22.3% over twelve months and by 9.6% year-to-date. Even with a modest uptick of 1.1% in the last month, Danaher still has not fully shaken concerns about shifting market sentiment and broader volatility in health sciences and industrial technology sectors. Looking further back, the five-year return of 14.8% serves...